Chemistry:Cagrilintide
Cagrilintide is a long-acting analogue of amylin. It is being tested to treat obesity and type 2 diabetes by itself and in combination with semaglutide as cagrilintide/semaglutide ("CagriSema").[1][2][3][4][5][6]
Research
A systematic review and metanalysis of cagrisema, published in 2024, found that cagrisema may provide weight loss benefits.[7]
Novo Nordisk announced late at the 2025 European Association for the Study of Diabetes (EASD) annual meeting that in the REDEFINE 1 study,[8] cagrilintide provided clinically significant weight loss, with a mean reduction in body weight of 11.8% compared to 2.3% with placebo after 68 weeks, considering adherence of all participants to treatment. In addition, approximately 1 in 3 participants (31.6%) who received cagrilintide achieved a weight loss ≥15%, compared to approximately 1 in 20 participants (4.7%) who received placebo.[9]
References
- ↑ Larsen, Anna T.; Sonne, Nina; Mohamed, Khaled Elhady; Bredtoft, Emma-Marie; Andersen, Frederik; Karsdal, Morten A.; Henriksen, Kim (1 June 2022). "823-P: The Long-Acting Dual Amylin and Calcitonin Receptor Agonist KBP Has Increased Efficacy on Weight Loss and Glucose Control Compared with Cagrilintide in Obese and Diabetic Rats". Diabetes 71 (Supplement_1). doi:10.2337/db22-823-P. https://diabetesjournals.org/diabetes/article/71/Supplement_1/823-P/146339.
- ↑ Lau, David C W; Erichsen, Lars; Francisco, Ann Marie; Satylganova, Altynai; le Roux, Carel W; McGowan, Barbara; Pedersen, Sue D; Pietiläinen, Kirsi H et al. (December 2021). "Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial" (in en). The Lancet 398 (10317): 2160–2172. doi:10.1016/S0140-6736(21)01751-7. PMID 34798060. https://discovery.ucl.ac.uk/id/eprint/10155031/.
- ↑ Kruse, Thomas; Hansen, Jakob Lerche; Dahl, Kirsten; Schäffer, Lauge; Sensfuss, Ulrich; Poulsen, Christian; Schlein, Morten; Hansen, Ann Maria Kruse et al. (12 August 2021). "Development of Cagrilintide, a Long-Acting Amylin Analogue" (in en). Journal of Medicinal Chemistry 64 (15): 11183–11194. doi:10.1021/acs.jmedchem.1c00565. ISSN 0022-2623. PMID 34288673.
- ↑ Frias, Juan P; Deenadayalan, Srikanth; Erichsen, Lars; Knop, Filip K; Lingvay, Ildiko; Macura, Stanislava; Mathieu, Chantal; Pedersen, Sue D et al. (August 2023). "Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial" (in en). The Lancet 402 (10403): 720–730. doi:10.1016/S0140-6736(23)01163-7. PMID 37364590.
- ↑ D'Ascanio, Antonella M.; Mullally, Jamie A.; Frishman, William H. (8 March 2023). "Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity". Cardiology in Review 32 (Publish Ahead of Print): 83–90. doi:10.1097/CRD.0000000000000513. PMID 36883831.
- ↑ Larsen, A. T.; Mohamed, K. E.; Sonne, N.; Bredtoft, E.; Andersen, F.; Karsdal, MA; Henriksen, K. (1 December 2022). "Does receptor balance matter? – Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models". Biomedicine & Pharmacotherapy 156. doi:10.1016/j.biopha.2022.113842. ISSN 0753-3322. PMID 36242844.
- ↑ "Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis". Indian Journal of Endocrinology and Metabolism 28 (5): 436–444. 2024. doi:10.4103/ijem.ijem_45_24. PMID 39676787.
- ↑ "REDEFINE 1". https://clinicaltrials.gov/study/NCT05567796.
- ↑ "Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity". New England Journal of Medicine 393 (7): 635–647. 2025. doi:10.1056/NEJMoa2502081. PMID 40544433.
 |  |
